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We report a case of a 59-year-old woman with brain metastases from an EGFR mutated
adenocarcinoma of the lung. She was initially treated with erlotinib and two times whole brain
radiation therapy. After a second relapse within the CNS the therapy was switched to geﬁtinib
and a partial remission of the brain metastases could be achieved. Our case demonstrates that
patients can respond to a switch of the EGFR TKI also within the CNS despite heavy pre-
treatment. The article reviews the literature regarding the efﬁcacy of tyrosine kinase inhibitors
in brain metastases from lung cancers.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Case presentation
A 59-year-old female patient presented with progressive
headaches over the course of two years. Magnetic resonance
imaging showed multiple brain metastases in the cerebrum
and cerebellum. Positron emission tomography-computed
tomography of the chest and abdomen revealed a primary.03.001
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ksgr.ch (C. Leitner).tumor in the medial lobe of the right lung and multiple
enlarged hilar, subcarinal and supraclavicular lymph nodes.
Furthermore, multiple bone metastases and a right sided
adrenal metastasis were described. Bronchoscopic ﬁne nee-
dle aspiration of a mediastinal lymph node showed adeno-
carcinoma cells. The activating mutation L858R in the
epidermal growth-factor-receptor (EGFR) gene within exon
21 could be detected by PCR-based assay. We initiated a
therapy with the tyrosine kinase inhibitor (TKI) erlotinib at a
dosage of 150 mg once daily. In addition a concomitant whole
brain radiation therapy (WBRT) with 5 4 Gy and a radiation
of the cervical spine with 5 4 Gy was applied. Severe
fatigue (grade 3) persisted after the WBRT for severalen access article under the CC BY-NC-ND license
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be reduced to 100 mg/d. Repeated computed tomography 2,
5, 8 and11 months after initiation of therapy showed
sustained partial remission in the lung and mediastinum as
well as in the CNS. The patient's overall condition markedly
improved over time with improvement of the headaches as
well as the dizziness and fatigue. A ﬁrst relapse with multiple
new brain metastases had to be diagnosed after 13 months of
therapy with erlotinib. At this point, repeated WBRT with
10 2 Gy was performed. Treatment with erlotinib was
interrupted during the course of radiotherapy. The local
response to treatment was good with a marked reduction
of the cerebral metastases. However, 4 months later, on
continued erlotinib therapy and 18 months after starting
treatment with erlotinib, a second relapse was noted. At this
point, the patient suffered from a deterioration of the
performance status (ECOG PS: 2–3), progressive cephalea
and dizziness. Computed tomography showed further pro-
gression in the CNS and extensive new hepatic and pulmonary
metastases. Neither the continuation of erlotinib nor con-
ventional chemotherapy seemed a reasonable treatment
option. The patient however desired further treatment and
we decided to switch the anti-EGFR-therapy to geﬁtinib
250 mg once daily. Within a few weeks, the patient's general
condition improved and a partial remission of all tumor
lesions including the CNS was noted in a follow up CT scan
after 3 months (Figure 1). A total of 5 months after the
initiation of geﬁtinib, further hepatic and cerebralFigure 1 Magnetic resonance imaging (MRI) and computed tomog
initial diagnosis (A), after ﬁrst line therapy with whole brain radiat
repeated WBRT and continued erlotinib (D), at second relapse (E),progression was noted. A last therapeutic attempt with
afatinib (30 mg/d) over eight weeks within a named patient
program remained without success and the patient died of
her disease 27 months after the initial diagnosis.2. Discussion
Lung cancer is still the most common malignancy with
estimated 1.3 million deaths per year worldwide [1]. More
than 80% of all cases are caused by non-small lung cancer
(NSCLC) [2]. About 20–30% of patients with NSCLC present
with brain metastases [3]. The prognosis of these patients is
generally poor with a median survival of less than 6 months
[4]. More than 60% of NSCLCs overexpress epidermal growth
factor receptor (EGFR) [5]. These transmembrane tyrosine
kinases transduce important growth factor signals from the
extracellular compartment into the cell. The tyrosine kinase
inhibitors (TKI) erlotinib and geﬁtinib target the intracel-
lular kinase domain of EGFR. They have been shown to be
particularly effective in tumors harboring activating muta-
tions in the tyrosine kinase domain of the EGFR gene, mainly
exon 19 deletions and exon 21 L858R point mutation [6].
Testing for these mutations in all patients with metastatic
non-squamous carcinoma of the lung is therefore recom-
mended and today standard practice [7]. Erlotinib and
geﬁtinib have both been compared against standard che-
motherapy regimens in several randomized phase III trials inraphy (CT) scans showing the process of brain metastases: at
ion therapy (WBRT) and erlotinib (B), at ﬁrst relapse (C), after
after therapy with geﬁtinib (F).
C. Leitner et al.6EGFR mutated patients and they demonstrated signiﬁcantly
improved response rate, progression free survival and
quality of life [8–11]. Therefore all guidelines recommend
initial therapy with a TKI instead of chemotherapy as the
best choice of treatment for patients with advanced NSCLC
and an activating EGFR mutation. In patients with brain
metastases from an EGFR mutated lung cancer, primary
treatment with geﬁtinib or erlotinib has also demonstrated
response in the CNS [12–15]. Porta et al. retrospectively
examined efﬁcacy and tolerability of erlotinib in 69 NSCLC
patients with brain metastases. Objective response rate in
patients with EGFR mutations (n=17) was 82.4% and
8 patients achieved a complete remission [12]. Therefore
WBRTcan be postponed in patients with asymptomatic brain
metastases and an activating EGFR mutation if patients
respond to geﬁtinib or erlotinib. The radiosensitivity of lung
cancer cells with mutant EGFR has been demonstrated in
in vitro studies [16]. In addition synergistic antitumor
effects between EGFR inhibitors and radiation have been
demonstrated in preclinical studies [17,18]. In a recent
phase II study concomitant WBRT and erlotinib was eval-
uated in 40 patients with brain metastases from NSCLC
regardless of the EGFR mutation status [19]. Overall
response rate was 86% and median survival was 11.8
months. The therapy was safe and particular beneﬁt was
evident for patients with EGFR mutations. The combination
of TKIs and WBRT therefore seems to be a safe and reason-
able treatment strategy. Regarding the question of switch-
ing from one TKI to another TKI in case of progression of
EGFR mutated NSCLC the only prospective data derive from
the LUX Lung 1 trial [20]. This trial tested the irreversible
TKI afatinib in patients who had previously received erloti-
nib or geﬁtinib and one or two lines of chemotherapy. The
trial included an unselected patient population. The sub-
group analysis of the EGFR mutated patients (N=96) showed
a signiﬁcantly longer progression-free survival for patients
receiving afatinib compared to those who received placebo
(3.3 months vs 1.0 months). A recently reported retro-
spective study showed that patients with advanced NSCLC
and activating mutations could beneﬁt from re-
administration of the same TKI after failure of erlotinib or
geﬁtinib [21]. In all of these patients (N=33), a conven-
tional chemotherapy was performed between the ﬁrst and
second TKI therapy. Switching of TKI or reintroduction of the
same TKI might therefore represent an option in previously
responding patients. Our case demonstrates, that patients
can not only respond to a switch of the TKI outside but also
within the CNS despite heavy pretreatment including two
times WBRT. The fact that a direct switch of TKI lead to this
result in the CNS is particularly unusual. The effectiveness
of TKIs on brain lesions is depending on drug penetration to
the CNS through the blood-brain-barrier (BBB). It is unclear,
whether one or the other TKI has better penetration
through the blood-brain barrier. In one report, erlotinib
demonstrated a response in patients with brain metastases
from NSCLC that appeared after good initial response of
extracranial disease to geﬁtinib [22] assuming different
penetration of the two agents. Several retrospective studies
examined drug concentrations in the cerebrospinal ﬂuid
(CSF) of patients with CNS metastases from NSCLC [23–25].
The results suggest higher CSF concentrations and better
control rates for erlotinib than for geﬁtinib. However, largerintracranial lesions may cause disruption of the BBB and
cause an ineffective barrier [26,27]. Moreover, radiotherapy
has been shown to increase the BBB permeability [28]. One
possible explanation for the unexpected success of geﬁtinib
in our patient could therefore be an increased disruption of
the BBB by tumor invasion and by post-radiogenic effects.
Only two case reports were found in our literature research
that showed a cross-over response of brain metastases to
one TKI after failure of another TKI [29,30]. The two most
common mechanisms of tumor resistance to TKIs are T790M
secondary mutation and MET gene ampliﬁcation. Cells with
these transformations are both resistant to erlotinib and
geﬁtinib [31]. The discordant response between erlotinib
and geﬁtinib was in one of the mentioned reports [30]
attributed to the EGFR mutation E884K. Also in our case
another mutation or an altered proportion of resistant or
sensitive tumor cells could be responsible for the resistance
to erlotinib and the continuing efﬁcacy to geﬁtinib. How-
ever such considerations remain speculative, as post-
mortem CNS tumor specimens were not examined. A further
explanation of our unusual result could be the dosage of
TKIs. It is known that higher doses may overcome resistance
to standard doses. Favorable effectiveness especially
toward intracranial metastases from NSCLC is described in
several reports [32,33]. In fact we used standard dosed
geﬁtinib (250 mg/d) whereas erlotinib had to be dose-
reduced (100 mg/d) because of severe skin rash. However,
erlotinib was still dosed closer to its maximal tolerated dosis
(150 mg/d) than geﬁtinib (750 mg/d). Finally, our patient
has had a relatively long beneﬁt from treatment with EGFR
TKIs without chemotherapy (27 months). We hypothesize
that in these patients a switch from one TKI to the other
could be of particular value.3. Conclusion
We report a case with good response of brain metastases to
geﬁtinib in an EGFR mutated adenocarcinoma of the lung
after progression on erlotinib and two times WBRT.Conﬂicts of interest statement
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The patient we describe in our case report died of her
disease prior to writing and submission of our manuscript.
Therefore no written and signed consent could be obtained
from the patient. Informed consent was obtained from the
patient's husband for publication of this case report and
accompanying images.
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